European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC
EBAC was delisted on the 2nd of March, 2023.
41 hedge funds and large institutions have $55.2M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
28% more capital invested
Capital invested by funds: $43M → $55.2M (+$12.2M)
28% more funds holding
Funds holding: 32 → 41 (+9)
9.56% more ownership
Funds ownership: 33.59% → 43.14% (+9.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$4.87M |
| 2 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
+$2.18M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.89M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$935K |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
+$709K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$183K |
EBAC Hedge Fund Activity: Q3 2021 in Review
41 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q3 2021, worth a combined $55.2M — up 28% from $43M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new EBAC positions and 0 closed out — a net gain of 9 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Macquarie Group, opening a new position worth an estimated $4.87M. The largest seller was Millennium Management, cutting an estimated $183K.
- 41 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q3 2021, up from 32 in Q2 2021.
- Funds reported $55.2M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q3 2021, up 28% quarter-over-quarter.
- 9 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q3 2021 and 0 closed out, a net change of +9 holders.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q3 2021 was Macquarie Group, an estimated $4.87M added.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q3 2021 was Millennium Management, an estimated $183K sold.
Based on aggregated 13F filings for Q3 2021.